Amgen(US:AMGN) Financial Modeling Prep·2026-01-20 22:06Core Viewpoint - Amgen Inc. is facing a potential increase in stock price according to Bernstein's target, but legal challenges may impact its performance and reputation [1][4][5]. Group 1: Stock Performance - Bernstein has set a price target of $335 for Amgen, suggesting a potential increase of about 1.38% from the current stock price of $330.06 [1][6]. - The stock has fluctuated today, with a low of $321.71 and a high of $330.83, reflecting its volatility [2]. - Over the past year, Amgen's stock has reached a high of $346.38 and a low of $261.43, indicating significant market fluctuations [2][6]. Group 2: Market Capitalization and Trading Activity - Amgen's market capitalization is approximately $177.73 billion, underscoring its substantial presence in the pharmaceutical industry [3]. - The trading volume for the day is 971,158 shares on the NASDAQ exchange, indicating active investor interest [3]. Group 3: Legal Challenges - Amgen is facing a lawsuit from Sagebrush Health Services, alleging unlawful termination of discounted drug sales, which could affect over 10,000 patients in Nevada [4]. - This legal issue may impact Amgen's reputation and financial performance, necessitating close monitoring by investors [5][6].